Prophylactic HPV vaccination and anal cancer

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1348-1351

  Stier, Elizabeth A ^a   Chigurupati, Nagasudha L ^a   Fung, Leslie ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anal cancer; HPV; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; ANUS CARCINOMA; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SCREENING; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; MEN WHO HAVE SEX WITH MEN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PAPILLOMAVIRUS INFECTION; SQUAMOUS CELL CANCER OF THE ANUS; UTERINE CERVIX CANCER; VACCINATION; ADOLESCENT; ADULT; ANUS NEOPLASMS; COMPLICATION; FEMALE; IMMUNOLOGY; INCIDENCE; MALE; TREATMENT OUTCOME; UTILIZATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANUS NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84964057114     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1149274     Document Type: Article

References (19)

1. Fact Sheet: Age-Adjusted SEER Incidence Rates By Cancer Site. National Cancer Institute, Surveillance, epidemiology and end results program (SEER), “anus, anal canal and anal rectum” All Ages, All Races, Male and female, 1975-2012 (SEER 9). Available from: http://seer.cancer.gov/faststats/selections.php?#Output
2. D.A.Machalek, M.Poynten, F.Jin, C.K.Fairley, A.Farnsworth, S.M.Garland, R.J.Hillman, K.Petoumenos, J.Roberts, S.N.Tabrizi, Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13:487-500; PMID:22445259; http://dx.doi.org/10.1016/S1470-2045(12)70080-3
3. E.A.Stier, M.C.Sebring, A.E.Mendez, F.S.Ba, D.D.Trimble, E.Y.Chiao. Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review. Am J Obstet Gynecol 2015; 213:278-309; PMID:25797230; http://dx.doi.org/10.1016/j.ajog.2015.03.034
4. H.De Vuyst, G.M.Clifford, M.C.Nascimento, M.M.Madeleine, S.Franceschi. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626-36; PMID:19115209; http://dx.doi.org/10.1002/ijc.24116
5. I.Baricevic, X.He, B.Chakrabarty, A.W.Oliver, C.Bailey, J.Summers, L.Hampson, I.Hampson, D.C.Gilbert, A.G.Renehan. High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Eur J Cancer 2015; 51:776-85; PMID:25702585; http://dx.doi.org/10.1016/j.ejca.2015.01.058
6. B.Serrano, S.de Sanjosé, S.Tous, B.Quiros, N.Muñoz, X.Bosch, L.Alemany. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer 2015; 51:1732-41; PMID:26121913; http://dx.doi.org/10.1016/j.ejca.2015.06.001
7. N.Ouhoummane, M.Steben, F.Coutlée, T.Vuong, P.Forest, C.Rodier, R.Louchini, E.Duarte, P.Brassard. Squamous anal cancer: patient characteristics and HPV type distribution. Cancer Epidemiol 2013; 37:807-12; PMID:24139594; http://dx.doi.org/10.1016/j.canep.2013.09.015
8. R.J.Hillman, S.M.Garland, M.P.W.Gunathilake, M.Stevens, N.Kumaradevan, C.Lemech, R.L.Ward, A.Meagher, L.McHugh, F.Jin, Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. Int J Cancer 2014; 135:996-1001; PMID:24497322; http://dx.doi.org/10.1002/ijc.28730
9. L.Alemany, M.Saunier, I.Alvarado-Cabrero, B.Quirós, J.Salmeron, H.R.Shin, E.C.Pirog, N.Guimerà, G.Hernandez-Suarez, A.Felix, Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer 2015; 136:98-107; PMID:24817381; http://dx.doi.org/10.1002/ijc.28963
10. M.Steinau, E.R.Unger, B.Y.Hernandez, M.T.Goodman, G.Copeland, C.Hopenhayn, W.Cozen, M.S.Saber, Y.Huang, E.S.Peters, Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis 2013; 17:397-403; PMID:23609590; http://dx.doi.org/10.1097/LGT.0b013e31827ed372
11. L.Abramowitz, A.-C.Jacquard, F.Jaroud, J.Haesebaert, L.Siproudhis, P.Pradat, O.Aynaud, Y.Leocmach, B.Soubeyrand, Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study. Int J Cancer 2011; 129:433-9; PMID:20839262; http://dx.doi.org/10.1002/ijc.25671
12. M.R.E.McCredie, K.J.Sharples, C.Paul, J.Baranyai, G.Medley, R.W.Jones, D.C.Skegg. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9:425-34; PMID:18407790; http://dx.doi.org/10.1016/S1470-2045(08)70103-7
13. J.M.Palefsky, A.R.Giuliano, S.Goldstone, E.D.MoreiraJr, C.Aranda, H.Jessen, R.Hillman, D.Ferris, F.Coutlee, M.H.Stoler, HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
14. J.M.Palefsky Screening to prevent anal cancer: Current thinking and future directions. Cancer Cytopathol 2015; 123:509-10; PMID:26237741; http://dx.doi.org/10.1002/cncy.21571
15. T.Wilkin, J.Y.Lee, S.Y.Lensing, E.A.Stier, S.E.Goldstone, J.M.Berry, N.Jay, D.Aboulafia, D.L.Cohn, M.H.Einstein, Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men. J Infect Dis 2010; 202:1246-53; PMID:20812850; http://dx.doi.org/10.1086/656320
16. Vaccine therapy in preventing Human papillomavirus infection in young HIV-positive male patients who have sex with males. In: ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01209325?term=NCT01209325 NLM Identifier: NCT01209325
17. K.A.Swedish, S.H.Factor, S.E.Goldstone. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis 2012; 54:891-8; PMID:22291111; http://dx.doi.org/10.1093/cid/cir1036
18. A.A.Deshmukh, J.Chhatwal, E.Y.Chiao, A.G.Nyitray, P.Das, S.B.Cantor. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. Clin Infect Dis 2015; 61:1527-35; PMID:26223993; http://dx.doi.org/10.1093/cid/civ628
19. E.A.Joura, A.R.Giuliano, O.-E.Iversen, C.Bouchard, C.Mao, J.Mehlsen, E.D.MoreiraJr, Y.Ngan, L.K.Petersen, E.Lazcano-Ponce, A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in Women. N Engl J Med 2015; 372(8):711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044